Doctor Kessler warns Congress about FDA cuts impacting food safety and drug regulation

The U.S. House Committee on Oversight and Government Reform convened on April 10, 2025, to discuss critical issues surrounding the Food and Drug Administration (FDA) and its ability to ensure public safety amid significant budget cuts. The meeting highlighted concerns about the FDA's capacity to regulate food safety and respond to health crises, particularly in light of recent staffing reductions.

One of the primary topics of discussion was the impact of budget cuts on the FDA's operations. Former FDA Commissioner Dr. David Kessler emphasized that the agency is facing a crisis due to the loss of experienced personnel. He likened the situation to an airline operating with only copilots, lacking the necessary expertise to ensure safety. Kessler warned that these cuts could jeopardize the FDA's ability to manage food safety, particularly in light of recent outbreaks, such as avian flu.

Committee members expressed their frustration over the misinformation surrounding food additives, particularly color additives, and the public's trust in the FDA. Concerns were raised about the potential health risks associated with certain additives, especially for children. One member argued that the FDA must prioritize natural ingredients over artificial additives to protect consumers.

The discussion also touched on the broader implications of losing expertise within the FDA and other health agencies. Kessler noted that the current cuts could hinder the development of future scientists and experts in the field, potentially setting back public health efforts for decades. He stressed the urgency of addressing these staffing issues before the damage becomes irreversible.

In conclusion, the committee's meeting underscored the critical need for a reassessment of the FDA's funding and staffing to restore public trust and ensure the safety of food and drugs in the United States. The discussions highlighted a growing concern that without immediate action, the FDA's ability to protect public health could be severely compromised.